Eli Lilly Share Holder Equity 2010-2024 | LLY

Eli Lilly share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
  • Eli Lilly share holder equity for the quarter ending March 31, 2024 was $12.897B, a 14.19% increase year-over-year.
  • Eli Lilly share holder equity for 2023 was $10.864B, a 0.82% increase from 2022.
  • Eli Lilly share holder equity for 2022 was $10.775B, a 17.7% increase from 2021.
  • Eli Lilly share holder equity for 2021 was $9.155B, a 57.16% increase from 2020.
Eli Lilly Annual Share Holder Equity
(Millions of US $)
2023 $10,864
2022 $10,775
2021 $9,155
2020 $5,825
2019 $2,699
2018 $10,909
2017 $11,668
2016 $14,081
2015 $14,590
2014 $15,388
2013 $17,641
2012 $14,774
2011 $13,536
2010 $12,413
2009 $9,525
Eli Lilly Quarterly Share Holder Equity
(Millions of US $)
2024-03-31 $12,897
2023-12-31 $10,864
2023-09-30 $11,307
2023-06-30 $11,149
2023-03-31 $11,295
2022-12-31 $10,775
2022-09-30 $10,166
2022-06-30 $8,659
2022-03-31 $9,462
2021-12-31 $9,155
2021-09-30 $7,954
2021-06-30 $6,664
2021-03-31 $7,099
2020-12-31 $5,825
2020-09-30 $4,996
2020-06-30 $4,272
2020-03-31 $3,197
2019-12-31 $2,699
2019-09-30 $3,462
2019-06-30 $2,857
2019-03-31 $2,565
2018-12-31 $10,909
2018-09-30 $14,151
2018-06-30 $11,621
2018-03-31 $14,588
2017-12-31 $11,668
2017-09-30 $14,961
2017-06-30 $14,170
2017-03-31 $14,104
2016-12-31 $14,081
2016-09-30 $15,616
2016-06-30 $14,656
2016-03-31 $15,029
2015-12-31 $14,590
2015-09-30 $15,241
2015-06-30 $14,705
2015-03-31 $14,947
2014-12-31 $15,388
2014-09-30 $17,683
2014-06-30 $17,995
2014-03-31 $18,349
2013-12-31 $17,641
2013-09-30 $16,896
2013-06-30 $15,236
2013-03-31 $14,956
2012-12-31 $14,774
2012-09-30 $16,057
2012-06-30 $14,308
2012-03-31 $14,823
2011-12-31 $13,536
2011-09-30 $15,058
2011-06-30 $14,277
2011-03-31 $13,934
2010-12-31 $12,413
2010-09-30 $12,406
2010-06-30 $10,235
2010-03-31 $10,462
2009-12-31 $9,525
2009-09-30 $9,905
2009-06-30 $8,560
2009-03-31 $7,725
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $824.287B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $642.884B 49.40
Johnson & Johnson (JNJ) United States $349.955B 13.90
Merck (MRK) United States $329.771B 60.00
AbbVie (ABBV) United States $293.293B 15.15
AstraZeneca (AZN) United Kingdom $248.255B 21.58
Novartis AG (NVS) Switzerland $215.744B 15.30
Pfizer (PFE) United States $156.738B 19.48
Sanofi (SNY) $122.543B 11.56
Innoviva (INVA) United States $0.993B 6.97